Title
Category
Credits
Event date
Cost
Part 1: Suspicion, Identification, and Evaluation of Patients Who May Have Early Alzheimer’s Disease Neurobiology
$0.00
Alzheimer’s disease (AD) is a complex condition to diagnose and treat due to its significant overlap in symptoms and even pathological elements with other conditions. Notably, only half of AD cases are diagnosed and, when they are, diagnosis typically occurs several years following symptom onset. These issues only worsen for patients evaluated during earlier stages of AD. Now that disease-modifying therapies (DMT) specifically targeting early AD pathology are beginning to enter the therapeutic armamentarium, early diagnosis is becoming more critical than ever.
Part 2: Importance and Implications of Biomarkers in Diagnosis and Modern Treatment of Alzheimer’s Disease
$0.00
Not only are cases of mild cognitive impairment (MCI) often not diagnosed, but more than 50% of these patients are misdiagnosed. One contributor to these observations is the fact that with biomarker assessments historically restricted (even in formal guidelines) to research, clinicians commonly rely on clinical scales, often with poor sensitivity to early stages, to generate suspicion of Alzheimer’s disease (AD).
Part 3: Evolving Roles in Alzheimer’s Disease Management: Team-Based Care in the Modern Age of Disease-Modifying Therapy
$0.00
Due to the growing complexity in the management of Alzheimer’s disease (AD), patient care falls under a wide umbrella of clinical team members across specialties, increasing the complexity of disease management. As successful team-based care was a challenge even prior to the introduction of biomarkers and disease-modifying therapies to clinical practice, individual team member recognition of and proficiency in their changing roles and responsibilities is critical to ensure new strategies are executed effectively.
Battle of the Biomarkers: Assessing Key Factors in Prognosis, Monitoring, and Therapeutic Decision-Making for Disease Worsening in Multiple Sclerosis
$0.00
OverviewOver the past several years, the image of MS has been changing from distinct categories of disease to a complicated spectrum of interwoven pathologies. As this knowledge evolves, so do approaches to prognosticating, monitoring, and responding to disease. With many markers of progression still under investigation and therefore not included in modern guidelines, MS clinicians are left on their own to decide which factors should hold the most weight in influencing clinical decisions.
A Deeper Look at Neuromyelitis Optica Spectrum Disorder: A Glimpse Onto the Clinic Floor with Specialists
$0.00
OverviewThough neuromyelitis optica spectrum disorder (NMOSD) has had a specific lab marker (AQP4 antibody) for many years, its relapsing nature and overlapping syndromes still causes it to be confused with multiple conditions such as multiple sclerosis (MS), leading to inappropriate and even harmful treatment. The emergence of similarly presenting MOG antibody disease as its own entity has further complicated the picture. Thankfully, FDA-approved targeted therapies have recently become available to treat NMOSD.
Stronger Together: Leveraging Evidence-Based Patient Collaboration and Treatment Strategies to Streamline Success in Multiple Sclerosis
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionWith the variety of possible risk factors, presentations, impacts, and preferences among individual patients with multiple sclerosis (MS), it has been well-established that every case of MS is unique. It is perhaps because of this that a collaborative, shared decision-making (SDM) approach has emerged as the preferred model of clinical care. However, in an age of over 20 FDA-approved disease modifying therapies (DMTs) and continuously evolving strategies for monitoring therapeutic response, the scope of shared clinical decisions is increasingly broad.
The Frontline of Alzheimer's Care: Addressing Real Questions from Clinicians in the New Dawn of Disease-Modifying Therapy
$0.00
Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD platform.Program DescriptionAlzheimer’s Disease (AD) has historically been a condition associated with more questions than answers.
On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management
$0.00
Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD platform.Program DescriptionThe field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease.
A Journey Through Migraine: Using Modern Evidence, Expert Insight, and Practice Simulation to Navigate Daily Challenges
$0.00
Due to the unique educational design of this course, the content must be viewed and completed on the myCME platform.Program Description1 in 6 adults in the US suffers from migraines, yet despite its widespread prevalence and burden, migraines continue to be underdiagnosed and undertreated.
When the Default is Not Enough: An Emergency Medicine Clinician's Guide to Novel Amyloid-Related Imaging Abnormalities in Alzheimer's Disease
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
 

Pages